Drug profile · INN
florbetapir f-18
AMYVID
florbetapir f-18 (AMYVID) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — florbetapir f-18
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
florbetapir f-18 (AMYVID) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
INN florbetapir f-18
Brand AMYVID
Mechanism Diagnostic agent
Route INTRAVENOUS
Formulation SOLUTION
Mechanism of action
Diagnostic agent
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is florbetapir f-18?
florbetapir f-18 (AMYVID) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for florbetapir f-18?
AMYVID is a marketed brand name for florbetapir f-18. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of florbetapir f-18?
florbetapir f-18 has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.